Therapeutic effect of trimetazidine on coronary heart disease combined chronic heart failure and its in‐fluence on cardiac function ,levels of plasma BNP and serum hsCRP / 心血管康复医学杂志

ABSTRACT

Objective:To study therapeutic effect of trimetazidine on coronary heart disease combined chronic heart failure (CHD‐CHF) and its influence on cardiac function ,levels of plasma BNP and serum hsCRP .Methods:A total of 92 CHD‐CHF patients treated in our hospital from Jan 2016 to Jun 2017 were randomly and equally divided into routine treatment group and trimetazidine group (received trimetazidine based on routine treatment ).Both groups were treated for three months.Heart rate (HR) ,blood pressure (BP) ,cardiac function indexes ,levels of plasma BNP and serum hsCRP before and after treatment ,and total effective rate were compared between two groups .Results:Total effective rate of trimetazi‐dine group was significantly higher than that of routine treatment group (95.65% vs.76.09%) , P＝0.007. Compared with routine treatment group after treatment ,there were significant reductions in HR [ (83.58 ± 5.17) beats／min vs. (72.69 ± 5.06) beats／min] ,BP [ (131.74 ± 12.98)／(83.25 ± 4.35) mmHg vs.(120.46 ± 12.53)／(79.25 ± 4.07) mmHg] ,LVESd [(41.21 ± 2.26) mm vs.(36.78 ± 2.07) mm] ,LVEDd [(57.91 ± 2.04) mm vs.(51.03 ± 1.89) mm] , levels of plasma BNP [ (262.94 ± 11.35) pg／ml vs.(223.42 ± 11.17) pg／ml] ,and serum hsCRP [ (5.86 ± 1.54) mg／L vs.(2.37 ± 0.95) mg／L] ,and significant rise in LVEF [ (53.72 ± 4.83)% vs.(61.37 ± 5.19)%] and 6MWD [ (285.42 ± 21.74) m vs.(376.08 ± 21.95) m] in trimetazidine group ,P＜0.01 all.Conclusion:Trimetazidine possesses significant therapeutic effect on CHD‐CHF.It can significantly improve cardiac function and reduce HR ,BP ,levels of plasma BNP and serum hsCRP ,which is worth extending .